1-13 of 13
Shumei Kato
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy

Available to Purchase
Jessica Jou, Shumei Kato, Hirotaka Miyashita, Kartheeswaran Thangathurai, Sarabjot Pabla, Paul DePietro, Mary K. Nesline, Jeffrey M. Conroy, Eitan Rubin, Ramez N. Eskander, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (11): 1352–1362.
https://doi.org/10.1158/1535-7163.MCT-23-0270
Published: 01 November 2023
View article titled, Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy
Open the PDF for Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy in another window
Includes: Supplementary data
Journal Articles

SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy

Available to Purchase
Kristina Mardinian, Jacob J. Adashek, Gregory P. Botta, Shumei Kato, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12): 2341–2351.
https://doi.org/10.1158/1535-7163.MCT-21-0433
Published: 03 December 2021
View article titled, SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy
Open the PDF for SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy in another window
Journal Articles

Abstract P226: Design and rationale of a first in human (FIH) phase 1/1b study evaluating KIN-2787, a potent and highly selective pan-RAF inhibitor, in adult patients with BRAF mutation positive solid tumors

Free
Meredith McKean, Shumei Kato, Alexander Spira, Yan Xing, Hao Xie, Elizabeth Buchbinder, Ken Kobayashi, Richard Williams
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P226.
https://doi.org/10.1158/1535-7163.TARG-21-P226
Published: 01 December 2021
View article titled, Abstract P226: Design and rationale of a first in human (FIH) phase 1/1b study evaluating KIN-2787, a potent and highly selective pan-RAF inhibitor, in adult patients with BRAF mutation positive solid tumors
Journal Articles

Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible

Open Access
Taylor J. Jensen, Aaron M. Goodman, Christopher K. Ellison, Kimberly A. Holden, Shumei Kato, Lisa Kim, Gregory A. Daniels, Kerry Fitzgerald, Erin McCarthy, Prachi Nakashe, Amin R. Mazloom, Eyad Almasri, Graham McLennan, Daniel S. Grosu, Marcia Eisenberg, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (11): 2274–2279.
https://doi.org/10.1158/1535-7163.MCT-20-1066
Published: 01 November 2021
View article titled, Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible
Open the PDF for Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible in another window
Journal Articles

Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA TP53 Mutations—A Perspective from a Real-World Precision Medicine Cohort

Free
Shai Rosenberg, Ryosuke Okamura, Shumei Kato, Thierry Soussi, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (12): 2612–2620.
https://doi.org/10.1158/1535-7163.MCT-20-0097
Published: 02 December 2020
View article titled, Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA TP53 Mutations—A Perspective from a Real-World Precision Medicine Cohort
Open the PDF for Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA TP53 Mutations—A Perspective from a Real-World Precision Medicine Cohort in another window
Includes: Supplementary data
Journal Articles

High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers

Free
Paul Riviere, Aaron M. Goodman, Ryosuke Okamura, Donald A. Barkauskas, Theresa J. Whitchurch, Suzanna Lee, Noor Khalid, Rachel Collier, Manvita Mareboina, Garrett M. Frampton, David Fabrizio, Andrew B. Sharabi, Shumei Kato, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (10): 2139–2145.
https://doi.org/10.1158/1535-7163.MCT-20-0161
Published: 02 October 2020
View article titled, High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers
Open the PDF for High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers in another window
Includes: Supplementary data
Journal Articles

Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics

Free
In Sil Choi, Shumei Kato, Paul T. Fanta, Lawrence Leichman, Ryosuke Okamura, Victoria M. Raymond, Richard B. Lanman, Scott M. Lippman, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2019) 18 (10): 1852–1862.
https://doi.org/10.1158/1535-7163.MCT-18-0965
Published: 01 October 2019
View article titled, Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics
Open the PDF for Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics in another window
Includes: Supplementary data
Journal Articles

Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis

Free
Filip Janku, Eli L. Diamond, Aaron M. Goodman, Vaijayanthi Kandadai Raghavan, Tamara G. Barnes, Shumei Kato, Omar Abdel-Wahab, Benjamin H. Durham, Funda Meric-Bernstam, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (6): 1149–1157.
https://doi.org/10.1158/1535-7163.MCT-18-1244
Published: 03 June 2019
View article titled, Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis
Open the PDF for Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis in another window
Journal Articles

Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients

Free
Taylor J. Jensen, Aaron M. Goodman, Shumei Kato, Christopher K. Ellison, Gregory A. Daniels, Lisa Kim, Prachi Nakashe, Erin McCarthy, Amin R. Mazloom, Graham McLennan, Daniel S. Grosu, Mathias Ehrich, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2019) 18 (2): 448–458.
https://doi.org/10.1158/1535-7163.MCT-18-0535
Published: 04 February 2019
View article titled, Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients
Open the PDF for Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Abstract LB-A07: Clinical utility of genomic assessment of blood-derived circulating tumor (ctDNA) in patients with colorectal cancers

Free
Maria C. Schwaederle, Shumei Kato, In Sil Choi, Paul T. Fanta, Lawrence Leichman, Scott Lippman, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-A07.
https://doi.org/10.1158/1535-7163.TARG-17-LB-A07
Published: 01 January 2018
View article titled, Abstract LB-A07: Clinical utility of genomic assessment of blood-derived circulating tumor (ctDNA) in patients with colorectal cancers
Journal Articles

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Free
Aaron M. Goodman, Shumei Kato, Lyudmila Bazhenova, Sandip P. Patel, Garrett M. Frampton, Vincent Miller, Philip J. Stephens, Gregory A. Daniels, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (11): 2598–2608.
https://doi.org/10.1158/1535-7163.MCT-17-0386
Published: 01 November 2017
View article titled, Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Open the PDF for Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers in another window
Includes: Supplementary data
Journal Articles

Genomic Landscape of Malignant Mesotheliomas

Free
Shumei Kato, Brett N. Tomson, Timon P.H. Buys, Sheryl K. Elkin, Jennifer L. Carter, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (10): 2498–2507.
https://doi.org/10.1158/1535-7163.MCT-16-0229
Published: 02 October 2016
View article titled, Genomic Landscape of Malignant Mesotheliomas
Open the PDF for Genomic Landscape of Malignant Mesotheliomas in another window
Includes: Supplementary data
Journal Articles

Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics

Free
Teresa Helsten, Shumei Kato, Maria Schwaederle, Brett N. Tomson, Timon P.H. Buys, Sheryl K. Elkin, Jennifer L. Carter, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (7): 1682–1690.
https://doi.org/10.1158/1535-7163.MCT-16-0071
Published: 05 July 2016
View article titled, Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics
Open the PDF for Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics in another window
Includes: Supplementary data